10-K Decoder · All companies

Sutro Biopharma, Inc.

STRO · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$102M$62.0M+65.2%
Operating income−$158M−$238M+33.6%
Net income−$191M−$227M+16.0%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 12, 2026

$Q3 2026Year earlierChange
Revenue$9.10M$9.70M−6.2%
Operating income−$22.0M−$48.5M+54.6%
Net income−$31.5M−$56.9M+44.6%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was Sutro Biopharma's revenue in FY2025?
$102M in FY2025 (Fiscal year ended Dec 31, 2025), +65.2% vs $62.0M a year earlier, per its 10-K filed Mar 2026.
Was Sutro Biopharma profitable in FY2025?
No: net income was −$191M and operating income −$158M in FY2025.
What was Sutro Biopharma's revenue in Q3 2026?
$9.10M (−6.2% vs a year earlier), per its Form 10-Q filed Nov 12, 2026.